PF-06838435
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for PF-06838435, covering 2024-03-27 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B [Phase 2]